An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Male and female subjects aged 18-65 years, inclusive
* BMI \>18 and \<40
* Minimum affected BSA of 10%
* PASI score ≥ 12
* PGA ≥ 3
* Diagnosed with moderate-to-severe plaque psoriasis
Exclusion Criteria:
* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
* History of an allergic reaction or known and/or significant sensitivity to study drug
Primary outcome measure(s)
Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs) — Through study completion, approximately 1 year Safety will be assessed based on frequency of treatment-emergent adverse events and serious adverse events, and frequency of clinically notable abnormal vital signs, blood chemistry, hematology, urology, and ECGs
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.